These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 15359567)

  • 1. The role of metabolites in bioequivalence.
    Midha KK; Rawson MJ; Hubbard JW
    Pharm Res; 2004 Aug; 21(8):1331-44. PubMed ID: 15359567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metabolites and bioequivalence: past and present.
    Jackson AJ; Robbie G; Marroum P
    Clin Pharmacokinet; 2004; 43(10):655-72. PubMed ID: 15244496
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioequivalence of chiral drugs. Stereospecific versus non-stereospecific methods.
    Mehvar R; Jamali F
    Clin Pharmacokinet; 1997 Aug; 33(2):122-41. PubMed ID: 9260035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computer simulations for bioequivalence trials: Selection of analyte in BCS class II and IV drugs with first-pass metabolism, two metabolic pathways and intestinal efflux transporter.
    Mangas-Sanjuan V; Navarro-Fontestad C; García-Arieta A; Trocóniz IF; Bermejo M
    Eur J Pharm Sci; 2018 May; 117():193-203. PubMed ID: 29452210
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I).
    Fernández-Teruel C; Nalda Molina R; González-Alvarez I; Navarro-Fontestad C; García-Arieta A; Casabó VG; Bermejo M
    Eur J Pharm Sci; 2009 Jan; 36(1):137-46. PubMed ID: 19028574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The bioequivalence of highly variable drugs and drug products.
    Midha KK; Rawson MJ; Hubbard JW
    Int J Clin Pharmacol Ther; 2005 Oct; 43(10):485-98. PubMed ID: 16240706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of metabolites in bioequivalence studies: should bioequivalence criteria be applied on the sum of parent compound and metabolite?
    Mahmood I
    Int J Clin Pharmacol Ther; 1998 Oct; 36(10):540-4. PubMed ID: 9799058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioequivalence: issues and options.
    Midha KK; Rawson MJ; Hubbard JW
    J Pharmacokinet Biopharm; 1997 Dec; 25(6):743-52. PubMed ID: 9697081
    [No Abstract]   [Full Text] [Related]  

  • 9. Considerations for metabolite pharmacokinetic data in bioavailability/bioequivalence assessments. Overview of the recent trends.
    Srinivas NR
    Arzneimittelforschung; 2009; 59(4):155-65. PubMed ID: 19517891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Examining the role of metabolites in bioequivalence assessment.
    Karalis V; Macheras P
    J Pharm Pharm Sci; 2010; 13(2):198-217. PubMed ID: 20816006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM; Nwakama PE; Buehler GJ; Conner DP; Haidar SH; Patel DT; Yang Y; Yu LX; Woodcock J
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acceptable and unacceptable procedures in bioavailability and bioequivalence trials.
    Marzo A; Ceppi Monti N
    Pharmacol Res; 1998 Nov; 38(5):401-4. PubMed ID: 9806821
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioequivalence studies: a new EMA guideline.
    Houin G
    Arzneimittelforschung; 2010; 60(4):169-70. PubMed ID: 20486464
    [No Abstract]   [Full Text] [Related]  

  • 14. The role of metabolites in bioequivalency assessment. II. Drugs with linear pharmacokinetics and first-pass effect.
    Chen ML; Jackson AJ
    Pharm Res; 1995 May; 12(5):700-8. PubMed ID: 7479556
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of variability in hepatic clearance on the bioequivalence parameters of a drug and its metabolite: simulations using a pharmacostatistical model.
    Rosenbaum SE
    Pharm Acta Helv; 1998 Aug; 73(3):135-44. PubMed ID: 9713258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulated drug bioanalysis for human pharmacokinetic studies and therapeutic drug management.
    Huang Y; Shi R; Gee W; Bonderud R
    Bioanalysis; 2012 Aug; 4(15):1919-31. PubMed ID: 22943622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The 2nd Calibration and Validation Group workshop on recent issues in good laboratory practice bioanalysis.
    Savoie N; Booth BP; Bradley T; Garofolo F; Hughes NC; Hussain S; King SP; Lindsay M; Lowes S; Ormsby E; Phull R; Rocci ML; Vallano PT; Viau A; Zhu Z
    Bioanalysis; 2009 Apr; 1(1):19-30. PubMed ID: 21083184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioavailability and bioequivalence trials: statistics & pharmacokinetic principles.
    Rajaram L; Roy SK; Skerjanec A
    Stud Health Technol Inform; 2004; 103():159-79. PubMed ID: 15747918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of Bayesian methods for multivariate bioequivalence measures.
    Molina de Souza R; Achcar JA; Martinez EZ
    J Biopharm Stat; 2009; 19(1):42-66. PubMed ID: 19127466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalent or nonbioequivalent?
    Rescigno A; Powers J; Herderick EE
    Pharmacol Res; 2001 Jun; 43(6):543-7. PubMed ID: 11419963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.